← All trials
NCT03332719
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2016
- Primary completion
- Mar 31, 2017
- Completion date
- Sep 30, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 168
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Gema Biotech S.A.Lead sponsor
- Atención Integral en ReumatologíaOverall official - principal investigator
- CAICIOverall official - principal investigator
- Centro Médico Privado de ReumatologíaOverall official - principal investigator
- Centro Reumatologico StrusbergOverall official - principal investigator
- CER San JuanOverall official - principal investigator
- Instituto Médico CEROverall official - principal investigator
- QUID Quality in Drugs and Devices Latin American Consulting SRLCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.